<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777175</url>
  </required_header>
  <id_info>
    <org_study_id>IRMLC</org_study_id>
    <nct_id>NCT04777175</nct_id>
  </id_info>
  <brief_title>A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer</brief_title>
  <official_title>A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yongchang Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS,&#xD;
      etc. The efficacy of these immunotherapies on these different rare mutations has not been&#xD;
      reported. Therefore, we conducted this retrospective clinical study to explore the efficacy&#xD;
      of immunotherapy for different rare mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>January 2021- January 2021 (1 year)</time_frame>
    <description>Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>KRAS mutation</arm_group_label>
    <description>patients carry with KRAS mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK fusion</arm_group_label>
    <description>patients carry with ALK fusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ERBB2 mutation</arm_group_label>
    <description>patients carry with ERBB2 mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MET skipping/amplication</arm_group_label>
    <description>patients carry with MET skipping/amplication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RET fusion</arm_group_label>
    <description>patients carry with RET fusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRAF mutation</arm_group_label>
    <description>patients carry with BRAF mutation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>immunity therapy</intervention_name>
    <description>The patient receives immunotherapy</description>
    <arm_group_label>ALK fusion</arm_group_label>
    <arm_group_label>BRAF mutation</arm_group_label>
    <arm_group_label>ERBB2 mutation</arm_group_label>
    <arm_group_label>KRAS mutation</arm_group_label>
    <arm_group_label>MET skipping/amplication</arm_group_label>
    <arm_group_label>RET fusion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced non-small-cell lung cancer carrying KRAS, ALK, ERBB2, MET, RET, BRAF&#xD;
        mutation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Diagnosed as advanced non-small cell lung cancer&#xD;
&#xD;
          -  2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is diagnosed with small cell lung cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>yangnong0217@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 27, 2021</last_update_submitted>
  <last_update_submitted_qc>February 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>HunanPTH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

